Al-Dawaa shareholders approve 2025 dividends
Shareholders of Spimaco Pharmaceuticals approved a cash dividend of 42 million SAR for the year 2025, representing 3.5% of the capital. They also voted to transfer the entire statutory reserve of 360.68 million SAR to retained earnings to strengthen the company's financial structure. Additionally, they approved incentive programs that include the purchase of up to 889,600 shares for the employee stock plan. They also approved amendments to the company's bylaws concerning share issuance and capital reduction, in accordance with the new Companies Law.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)